{
    "root": "186fcd68-438e-427f-ae19-8042c15baa78",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Trintellix",
    "value": "20250305",
    "ingredients": [
        {
            "name": "VORTIOXETINE HYDROBROMIDE",
            "code": "TKS641KOAY",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_76015"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (90000 WAMW)",
            "code": "UKE75GEA7F",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "trintellix indicated treatment major depressive disorder ( mdd ) adults .",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended starting dose 10 mg administered orally daily without regard meals ( 2.1 ) . dose increased 20 mg/day , tolerated ( 2.1 ) . consider 5 mg/day patients tolerate higher doses ( 2.1 ) . trintellix discontinued abruptly . however , recommended doses 15 mg/day 20 mg/day reduced 10 mg/day one week prior full discontinuation possible ( 2.3 ) . maximum recommended dose 10 mg/day known cyp2d6 poor metabolizers ( 2.5 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "trintellix tablets available follows : features strengths 5 mg 10 mg 20 mg color pink yellow red debossment `` 5 `` one side tablet `` 10 `` one side tablet `` 20 `` one side tablet `` tl `` side tablet `` tl `` side tablet `` tl `` side tablet presentations ndc codes bottles 30 64764-720-30 64764-730-30 64764-750-30 bottles 90 64764-720-90 64764-730-90 64764-750-90 bottles 500 64764-720-77 64764-730-77 64764-750-77",
    "adverseReactions": "hypersensitivity vortioxetine component formulation . hypersensitivity including anaphylaxis , angioedema , urticaria reported patients treated trintellix [ ( 6.2 ) ] . maois intended treat psychiatric disorders trintellix within 21 days stopping treatment trintellix contraindicated increased risk serotonin syndrome . trintellix within 14 days stopping maoi intended treat psychiatric disorders also contraindicated [ ( 2.4 ) , ( 5.2 ) ] . starting trintellix patient treated maois linezolid intravenous methylene blue also contraindicated increased risk serotonin syndrome [ ( 5.2 ) ] .",
    "indications_original": "TRINTELLIX is indicated for the treatment of major depressive disorder (MDD) in adults.",
    "contraindications_original": "The recommended starting dose is 10 mg administered orally once daily without regard to meals ( 2.1 ). The dose should then be increased to 20 mg/day, as tolerated ( 2.1 ). Consider 5 mg/day for patients who do not tolerate higher doses ( 2.1 ). TRINTELLIX can be discontinued abruptly. However, it is recommended that doses of 15 mg/day or 20 mg/day be reduced to 10 mg/day for one week prior to full discontinuation if possible ( 2.3 ). The maximum recommended dose is 10 mg/day in known CYP2D6 poor metabolizers ( 2.5 ).",
    "warningsAndPrecautions_original": "TRINTELLIX tablets are available as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           Features\n                           Strengths\n                        \n                        \n                           \n                           5 mg\n                           10 mg\n                           20 mg\n                        \n                     \n                     \n                        \n                           Color\n                           pink\n                           yellow\n                           red\n                        \n                        \n                           Debossment\n                           \"5\" on one side of tablet\n                           \"10\" on one side of tablet\n                           \"20\" on one side of tablet\n                        \n                        \n                           \n                           \"TL\" on other side of tablet\n                           \"TL\" on other side of tablet\n                           \"TL\" on other side of tablet\n                        \n                        \n                           \n                              Presentations and NDC Codes\n                           \n                        \n                        \n                           Bottles of 30\n                           64764-720-30\n                           64764-730-30\n                           64764-750-30\n                        \n                        \n                           Bottles of 90\n                           64764-720-90\n                           64764-730-90\n                           64764-750-90\n                        \n                        \n                           Bottles of 500\n                           64764-720-77\n                           64764-730-77\n                           64764-750-77",
    "adverseReactions_original": "Hypersensitivity to vortioxetine or any component of the formulation. Hypersensitivity reactions including anaphylaxis, angioedema, and urticaria have been reported in patients treated with TRINTELLIX [see Adverse Reactions (6.2)].\n                     The use of MAOIs intended to treat psychiatric disorders with TRINTELLIX or within 21 days of stopping treatment with TRINTELLIX is contraindicated because of an increased risk of serotonin syndrome. The use of TRINTELLIX within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [see Dosage and Administration (2.4), Warnings and Precautions (5.2)]. Starting TRINTELLIX in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2)].",
    "drug": [
        {
            "name": "Trintellix",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_76015"
        }
    ]
}